A Phase 2 interventional study of Atomoxetine and PNU-165442G; [S,S]-reboxetine in Attention Deficit Hyperactivity Disorder, sponsored by Pfizer. Withdrawn. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2019-04-16.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
This study will compare the safety and efficacy of [S,S]-reboxetine to atomoxetine in the treatment of adult patients with attention deficity-hyperactivity disorder.
729 studies on the registry are indexed under Hyperkinesis; 25 are open to participants now.
Browse Hyperkinesis studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: PNU-165442G; [S,S]-reboxetine
Drug: Atomoxetine
Adult ADHD Investigator Symptom Rating Scale - Total Score
Time frame: 4 weeks
Adult ADHD Investigator Symptom Rating Scale - Inattention Subscale Score
Time frame: 4 weeks
Adult ADHD Investigator Symptom Rating Scale - Hyperactivity/Impulsivity Subscale Score
Time frame: 4 weeks
No study locations are listed for this record.
This study is withdrawn, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer